Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...
Researchers are looking at ways to boost the performance and lower the environmental impact of millions of inhalers used for treating asthma and COPD. Working with drug manufacturer Kindeva, ...
AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback